Simple Summary Leukemia stem cells (LSCs) are rare cell populations present in acute
myeloid leukemia (AML) that are resistant to chemotherapy and cause disease relapse in …

Accumulating evidence support the notion that acute myeloid leukemia (AML) is organized
in a hierarchical system, originating from a special proportion of leukemia stem cells (LSC) …

Acute myeloid leukemia (AML) is considered to be a disease of stem cells. A rare defective
stem cell population is purported to drive tumor growth. Similarly to their normal …

Acute myeloid leukemia is an aggressive hematopoietic stem cell malignancy with poor
outcomes despite the available treatment options including standard chemotherapy …

Despite reaching remission with traditional chemotherapy, most adult patients with acute
myeloid leukemia (AML) will relapse and die of their disease. Numerous studies have …

Acute myelogenous leukemia (AML) is a genetically heterogeneous and aggressive cancer
of the Hematopoietic Stem/progenitor cells. It is distinguished by the uncontrollable clonal …

One of the distinguishing properties of hematopoietic stem cells is their ability to self-renew.
Since self-renewal is important for the continuous replenishment of the hematopoietic stem …

Present evidence indicates that acute myeloid leukemia (AML) is a stem cell disease.
Leukemia stem cells (LSC) might originate from malignant transformation of normal …

Evidence for the cancer stem cell model was first demonstrated in xenotransplanted blood
and bone marrow samples from patients with acute myeloid leukemia (AML) almost two …

In acute myeloid leukemia (AML), a small cell population that contains stem cell features
such as lack of differentiation, self-renewal potential, and drug resistance, can be identified …